Oncolytics Biotech Expects Final GOBLET Cohort 4 Results in Q4 2026

Bitget2026/10/14 13:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Oncolytics Biotech expects final GOBLET Cohort 4 results in fourth-quarter 2026; initial Cohort 5 results are expected in first-half 2027.
Cohort 4 tests pelareorep with atezolizumab in anal cancer; Cohort 5 evaluates pelareorep-based combinations in previously untreated metastatic pancreatic cancer.
Every fully enrolled cohort met its prespecified efficacy success criteria; survival in Cohort 4 exceeded expectations, while Cohort 5 outcomes continue maturing.
Cohort 5 reporting could slip as patients remain under treatment or follow-up; findings will guide pelareorep’s development with checkpoint inhibitors.
The final PanCAN grant payment is expected this quarter, with enrollment complete; broader study infrastructure is winding down while patient follow-up continues.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610140930PRIMZONEFULLFEED9845215) on October 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Oncolytics Biotech Expects Final GOBLET Cohort 4 Results in Q4 2026

You may also like

Crypto prices